Narrative review / 2018
A review highlights controversy over homocysteine as a risk factor for cardiovascular disease and stroke, as trials fail to show benefit from lowering it.
A focused Medline search from 2010 to 2017 identified 38 papers evaluating homocysteine as a risk factor for cardiovascular disease, atherosclerosis, and stroke. While observational studies and initial evidence suggested associations and potential preventive benefits of folic acid with or without B vitamins, subsequent prospective, randomized, placebo-controlled trials did not demonstrate an association of high homocysteine levels or their lowering with CVD, atherosclerosis, or stroke incidence. The author notes this discrepancy may be due to flour fortification with folic acid, leaving the clinical utility of homocysteine screening controversial.
- Study type
- Literature review
- Who was studied
- 38 papers identified from Medline (2010–2017)
- What was measured
- Significance of homocysteine and its treatment in CVD, atherosclerosis, and stroke
THE PAPER
The current status of homocysteine as a risk factor for cardiovascular disease: a mini review.
Chrysant SG, Chrysant GS. Expert Rev Cardiovasc Ther, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.